Skip to content
Companies

Medicovestor

Dimeric antibody-drug conjugates for low-antigen tumors

Raised to date

$3.2M

of $4.1M offered across 1 Form D filing

Still open
$900K
Investors
60
Last filed
Dec 5, 2025

About

Medicovestor is an early-stage biopharmaceutical company founded in 2023, focused on developing next-generation antibody-drug conjugate (ADC) platforms. The company aims to create precision medicines for solid tumors like pancreatic and ovarian cancer by overcoming the limitations of existing ADCs, particularly in tumors with low antigen expression.

The company's core innovation is its proprietary dimeric ADC platform, which is designed to functionally increase tumor antigen density and utilizes backbone antibodies with intrinsic antitumor activity, enabling a multi-pronged attack on cancer cells.

Funding

  • EquityFiled Dec 5, 2025Form D
    $3.2M/ $4.1M

Product

Dimeric ADC Platform

ADC Technology Platform

A proprietary, platform-agnostic technology for creating antibody-drug conjugates. It is designed to enhance the effective density of antigens on tumor cells, thereby improving the efficacy of ADCs, especially against tumors that express low levels of the target antigen. The platform's design also allows for multiple mechanisms of tumor cell killing.

  • Antigen-, antibody-, indication-, and payload-agnostic for broad applicability
  • Functionally increases tumor antigen density to improve efficacy in challenging tumors
  • Utilizes backbone antibodies with intrinsic antitumor activity for added cytotoxicity

Built for

Pharmaceutical and biotechnology companies are the primary target for partnerships, licensing agreements, and co-development opportunities.

People on file